QTTB

About Q32 Bio Inc. Common Stock (QTTB) Stock

Q32 Bio Inc. Common Stock (QTTB) closed the 2026-09-18 session at $10.54, down 2.95% versus the previous close (-0.32). The stock opened at $10.84 and traded between $10.46 and $10.97 during that session. Session trading volume was 972K shares. The volume-weighted average price (VWAP) is $10.57.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Q32 Bio Inc. Common Stock has a market capitalization of $313.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. QTTB is listed on the XNAS exchange. The company employs approximately 22 people. Q32 Bio Inc. Common Stock is headquartered in WALTHAM, MA. The recorded listing date is 2024-03-26.

On this page you can find market QTTB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.